Kenneth Mashburn, MD
Family Medicine · Hartselle, ALNPI 1578524369
Payments from drug & device makers
Across 492 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- AbbVie$715
- Boehringer Ingelheim$657
- Amarin Pharma, Inc.$440
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,567100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $1,298 |
| AstraZeneca | 50 | $1,273 |
| Lilly USA, LLC | 60 | $1,001 |
| AbbVie(2 entities) | 61 | $715 |
| Boehringer Ingelheim | 38 | $657 |
| Amarin Pharma, Inc. | 25 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $336 |
| Amgen(2 entities) | 22 | $320 |
| Pfizer | 15 | $274 |
| Sanofi-aventis U.S. LLC | 15 | $237 |
| GSK | 12 | $234 |
| Merck | 13 | $204 |
| Exact Sciences | 9 | $181 |
| Ironshore Pharmaceuticals Inc. | 6 | $180 |
| Johnson & Johnson | 7 | $131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $122 |
| Arbor Pharmaceuticals, Inc. | 8 | $106 |
| Astellas Pharma US Inc | 5 | $102 |
| Adlon Therapeutics L.p. | 7 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Dexcom, Inc. | 5 | $89 |
| Novartis | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Corium, LLC | 9 | $56 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Mylan Specialty L.p. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Shield Therapeutics Inc | 1 | $25 |
| Abbott | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Nalpropion Pharmaceuticals LLC | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,592 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $105,503 |
| FarxigaDapagliflozin Propanediol | 96 | $96,967 |
| EliquisApixaban | 118 | $87,718 |
| TrulicityDulaglutide | 83 | $79,003 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 74 | $70,865 |
| JardianceEmpagliflozin | 67 | $69,626 |
| OzempicSemaglutide | 45 | $45,713 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $40,906 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 43 | $37,240 |
| JanuviaSitagliptin Phosphate | 27 | $26,190 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $26,153 |
| Repatha SureclickEvolocumab | 35 | $25,885 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $23,126 |
| EntrestoSacubitril/Valsartan | 18 | $21,437 |
| Xigduo XrDapaglifloz Propaned/Metformin | 48 | $20,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,001 | $184,506165 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Stiolto Respimat | $657 | $122,433144 claims |
| AstraZenecaFarxiga | $1,273 | $96,96796 claims |
| PfizerEliquis | $274 | $87,718118 claims |
| MerckJanumet Xr, Januvia, Belsomra | $204 | $72,84292 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $237 | $70,86574 claims |
| Novo NordiskOzempic, Rybelsus | $1,298 | $66,09663 claims |
| GSKTrelegy Ellipta | $234 | $40,90640 claims |
| NovartisEntresto | $75 | $21,43718 claims |
| AbbVieLinzess | $715 | $17,99822 claims |
| Johnson & JohnsonXarelto | $131 | $17,31714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Hartselle
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.